| The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis M Roederer, L Quaye, M Mangino, MH Beddall, Y Mahnke, ... Cell 161 (2), 387-403, 2015 | 319 | 2015 |
| HDAC inhibition potentiates immunotherapy in triple negative breast cancer M Terranova-Barberio, S Thomas, N Ali, N Pawlowska, J Park, G Krings, ... Oncotarget 8 (69), 114156, 2017 | 151 | 2017 |
| Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer M Terranova-Barberio, N Pawlowska, M Dhawan, M Moasser, AJ Chien, ... Nature communications 11 (1), 3584, 2020 | 136 | 2020 |
| Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway A Leone, MS Roca, C Ciardiello, M Terranova-Barberio, C Vitagliano, ... Free Radical Biology and Medicine 89, 287-299, 2015 | 77 | 2015 |
| Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors M Terranova-Barberio, S Thomas, PN Munster Immunotherapy 8 (6), 705-719, 2016 | 71 | 2016 |
| Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression M Terranova-Barberio, MS Roca, AI Zotti, A Leone, F Bruzzese, ... Oncotarget 7 (7), 7715, 2016 | 70 | 2016 |
| The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients P Di Meglio, F Villanova, L Napolitano, I Tosi, MT Barberio, RK Mak, ... Journal of Investigative Dermatology 133 (10), 2381-2389, 2013 | 66 | 2013 |
| Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors MS Dhawan, IH Bartelink, RR Aggarwal, J Leng, JZ Zhang, N Pawlowska, ... Clinical Cancer Research 23 (21), 6400-6410, 2017 | 61 | 2017 |
| Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid-short … A Avallone, MC Piccirillo, P Delrio, B Pecori, E Di Gennaro, L Aloj, ... BMC cancer 14, 1-12, 2014 | 40 | 2014 |
| Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53 M Terranova-Barberio, B Pecori, MS Roca, S Imbimbo, F Bruzzese, ... Journal of Experimental & Clinical Cancer Research 36 (1), 1-13, 2017 | 34 | 2017 |
| Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma B Apollonio, F Spada, N Petrov, D Cozzetto, D Papazoglou, P Jarvis, ... The Journal of clinical investigation 133 (13), 2023 | 12 | 2023 |
| Clinical applications of histone deacetylase inhibitors J Park, M Terranova-Barberio, AY Zhong, S Thomas, PN Munster Handbook of Epigenetics, 605-621, 2017 | 12 | 2017 |
| Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer J Park, S Thomas, AY Zhong, AR Wolfe, G Krings, M Terranova-Barberio, ... Scientific reports 8 (1), 92, 2018 | 8 | 2018 |
| Autologous fat grafting as a novel anti-estrogen vehicle for the treatment of breast cancer S Thomas, S Chen, H Sbitany, E Kwon, M Pepir, J Park, MT Barberio, ... Plastic and reconstructive surgery 140 (3), 537, 2017 | 8 | 2017 |
| Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627). M Terranova Barberio, S Thomas, AJ Chien, HS Rugo, ME Melisko, ... Journal of Clinical Oncology 34 (15_suppl), TPS620-TPS620, 2016 | 5 | 2016 |
| Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients P Karagiannis, I Correa, J Chauhan, A Cheung, D Dominguez-Rodriguez, ... Clinical and Experimental Immunology 207 (1), 84-94, 2022 | 4 | 2022 |
| Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint … PN Munster, M Terranova Barberio, N Pawlowska, M Moasser, AJ Chien, ... Journal of Clinical Oncology 36 (15_suppl), 1044-1044, 2018 | 3 | 2018 |
| Host histone acetylation unlocks HDAC inhibitor potential M Terranova-Barberio, S Thomas, PN Munster Oncotarget 8 (63), 106161, 2017 | 3 | 2017 |
| B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma S Crescioli, I Correa, J Ng, ZN Willsmore, R Laddach, A Chenoweth, ... Nature Communications 14 (1), 3378, 2023 | 2 | 2023 |
| Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer as a rationale for the innovative V-shoRT-R3 trial in locally … M Terranova-Barberio, B Pecori, S Imbimbo, A Leone, F Bruzzese, ... Cancer Research 75 (15 Supplement), 2569-2569, 2015 | 1 | 2015 |
